These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20417357)

  • 1. How to evaluate the benefit-risk profile of newly marketed drugs.
    Naldi L
    Ann Dermatol Venereol; 2010 Apr; 137(4):264-6, 261-3. PubMed ID: 20417357
    [No Abstract]   [Full Text] [Related]  

  • 2. [Overseas Drug Safety Information 2008. Risk of infectious diseases associated with the use of immunosuppressive drugs].
    Amanuma K; Morikawa K
    Jpn J Antibiot; 2009 Oct; 62(5):460-70. PubMed ID: 20055123
    [No Abstract]   [Full Text] [Related]  

  • 3. [A chance we take...].
    Paley-Vincent C
    Ann Dermatol Venereol; 2010 Apr; 137(4):257-9. PubMed ID: 20417355
    [No Abstract]   [Full Text] [Related]  

  • 4. [Splendours and miseries of the benefit-risk ratio].
    Dupuy A
    Ann Dermatol Venereol; 2010 Apr; 137(4):267-8. PubMed ID: 20417358
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe fungal infections linked to drugs.
    Kuehn BM
    JAMA; 2008 Oct; 300(14):1639. PubMed ID: 18840827
    [No Abstract]   [Full Text] [Related]  

  • 6. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.
    Askling J; Fahrbach K; Nordstrom B; Ross S; Schmid CH; Symmons D
    Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):119-30. PubMed ID: 21254282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hazards of hindsight--monitoring the safety of nutritional supplements.
    Cohen PA
    N Engl J Med; 2014 Apr; 370(14):1277-80. PubMed ID: 24693886
    [No Abstract]   [Full Text] [Related]  

  • 9. Inconsistencies in reporting of granulomatous infectious diseases associated with infliximab and etanercept.
    Schaible TF
    Clin Infect Dis; 2004 Oct; 39(8):1255-6; author reply 1256. PubMed ID: 15486858
    [No Abstract]   [Full Text] [Related]  

  • 10. Tysabri risk causing headache for companies.
    Sheridan C
    Nat Rev Drug Discov; 2005 Sep; 4(9):703-4. PubMed ID: 16178114
    [No Abstract]   [Full Text] [Related]  

  • 11. [The experience of anti-TNF-alpha registries and observatories].
    Sibilia J; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):18-21. PubMed ID: 20510167
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Okada SK; Siegel JN
    JAMA; 2006 Nov; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of biologic therapies--an update.
    Keystone EC
    J Rheumatol Suppl; 2005 Mar; 74():8-12. PubMed ID: 15742458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration.
    Diak P; Siegel J; La Grenade L; Choi L; Lemery S; McMahon A
    Arthritis Rheum; 2010 Aug; 62(8):2517-24. PubMed ID: 20506368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons for clinical trials from natalizumab in multiple sclerosis.
    Chaudhuri A
    BMJ; 2006 Feb; 332(7538):416-9. PubMed ID: 16484271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tysabri's return draws cautious optimism. Pharmacies, infusion centers must register to participate.
    Traynor K
    Am J Health Syst Pharm; 2006 Aug; 63(15):1388, 1392. PubMed ID: 16849700
    [No Abstract]   [Full Text] [Related]  

  • 19. Tuberculosis screening in prescribers of anti-tumor necrosis factor therapy in the European Union.
    Smith MY; Attig B; McNamee L; Eagle T
    Int J Tuberc Lung Dis; 2012 Sep; 16(9):1168-73. PubMed ID: 22794309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS).
    Schmedt N; Andersohn F; Garbe E
    Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1216-20. PubMed ID: 22821419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.